Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials
- PMID: 12637113
- DOI: 10.1016/s0149-2918(03)90011-7
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials
Abstract
Background: Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain. Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated. Many cases are refractory to the medications traditionally used for pain, such as nonsteroidal anti-inflammatory drugs. Tricyclic antidepressants are considered first-line agents for neuropathic pain, but their use is limited by unwanted side effects and a risk of cardiovascular mortality.
Objectives: The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule.
Methods: Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain. Abstracts of identified articles were screened for study size (>100 patients per treatment arm) and use of appropriate efficacy measures. A separate review based on information provided by the manufacturer of gabapentinaand clinical trial Web sites was conducted to ascertain whether there had been any other relevant industry- or government-sponsored trials. The manufacturer provided additional unpublshed study data.
Results: Data from 5 randomized, placebo-controlled trials were included in the review, 1 of which has not yet been published. Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes. It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia. Adverse effects were typically mild to moderate and usually subsided within approximately 10 days from the initiation of treatment. Based on available data, it appears that treatment should be started at a dose of 900 mg/d (300 mg/d on day 1, 600 mg/d on day 2, and 900 mg/d on day 3). Additional titration to 1800 mg/d is recommended for greater efficacy. Doses up to 3600 mg/d may be needed in some patients. The effective dose should be individualized according to patient response and tolerability.
Conclusion: At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain.
Similar articles
-
Nortriptyline for neuropathic pain in adults.Cochrane Database Syst Rev. 2015 Jan 8;1(1):CD011209. doi: 10.1002/14651858.CD011209.pub2. Cochrane Database Syst Rev. 2015. PMID: 25569864 Free PMC article. Review.
-
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.Cochrane Database Syst Rev. 2014 Apr 27;2014(4):CD007938. doi: 10.1002/14651858.CD007938.pub3. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2017 Jun 09;6:CD007938. doi: 10.1002/14651858.CD007938.pub4. PMID: 24771480 Free PMC article. Updated. Review.
-
The use of gabapentin for the treatment of postherpetic neuralgia.Clin Ther. 2003 Mar;25(3):852-89. doi: 10.1016/s0149-2918(03)80111-x. Clin Ther. 2003. PMID: 12852705 Review.
-
[Gabapentin--yet another antiepileptic agent for the treatment of neuropathic pain?].Ugeskr Laeger. 2001 Jan 22;163(4):454-8. Ugeskr Laeger. 2001. PMID: 11218787 Review. Danish.
-
Postherpetic neuralgia: role of gabapentin and other treatment modalities.Epilepsia. 1999;40 Suppl 6:S51-6; discussion S73-4. doi: 10.1111/j.1528-1157.1999.tb00933.x. Epilepsia. 1999. PMID: 10530683 Review.
Cited by
-
Gabapentinoid prescriptions for neuropathic and musculoskeletal pain in Lebanon.Future Sci OA. 2024 May 14;10(1):FSO960. doi: 10.2144/fsoa-2023-0219. eCollection 2024. Future Sci OA. 2024. PMID: 38817381 Free PMC article.
-
Role of Palliative Care in the Supportive Management of AL Amyloidosis-A Review.J Clin Med. 2024 Mar 29;13(7):1991. doi: 10.3390/jcm13071991. J Clin Med. 2024. PMID: 38610755 Free PMC article. Review.
-
Analyzing the Antinociceptive Effect of Interleukin-31 in Mice.Int J Mol Sci. 2023 Jul 17;24(14):11563. doi: 10.3390/ijms241411563. Int J Mol Sci. 2023. PMID: 37511321 Free PMC article.
-
Mechanisms of Transmission and Processing of Pain: A Narrative Review.Int J Environ Res Public Health. 2023 Feb 9;20(4):3064. doi: 10.3390/ijerph20043064. Int J Environ Res Public Health. 2023. PMID: 36833753 Free PMC article. Review.
-
Effectiveness of Short-term Use of Gabapentin as Pre-emptive Analgesia in Reducing Pain after Video Assisted Thoracoscopic Surgery.Tanaffos. 2022 Jan;21(1):90-95. Tanaffos. 2022. PMID: 36258911 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical